Company Overview
Tarsus Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical entity dedicated to the development and commercialization of therapeutic candidates specifically targeting eye care within the United States market. The company functions within the broader Healthcare sector and the specialized Biotechnology industry, positioning itself to address unmet medical needs through innovative pharmaceutical solutions. As of the latest reported data, the organization employs 370 individuals and holds a market capitalization of $2.84 billion while generating $451.36 million in annual revenue. These valuation and revenue figures indicate that Tarsus has achieved significant scale and market recognition, establishing it as a substantial player capable of funding extensive research and development activities for its pipeline. The substantial market cap relative to its revenue base suggests that the market values the company's future potential and proprietary assets, such as its XDEMVY lotilaner ophthalmic solution, at a premium over current earnings performance.
Financial Health
The company reported revenue of $451.36 million over the trailing twelve months, yet this top-line figure is associated with a net income loss of $66.418 million and an EBITDA loss of $69.153 million. The significant gap between positive revenue and substantial negative net income reveals a cost structure where operating expenses, likely driven by research, development, and commercialization efforts, heavily outweigh gross profits. Free cash flow stands at $-164,000, indicating that while the company generates revenue, its current cash burn is relatively contained compared to its massive cash reserves, suggesting a degree of financial flexibility despite negative earnings. Profitability metrics are currently suppressed, with a gross margin of 79.0%, an operating margin of -5.3%, and a profit margin of -14.7%, where the high gross margin implies efficient production costs but the negative operating and profit margins reflect the heavy investment required to bring therapies to market. The balance sheet is fortified by $417.27 million in cash against $83.04 million in debt, resulting in a debt-to-equity ratio of 24.18 which, while high on a numerical basis, is often typical for capital-intensive biotechnology firms reliant on equity financing. Liquidity is robust with a current ratio of 3.85, indicating that the company holds more than three times the current assets necessary to cover its short-term liabilities without immediate distress. Return on Equity is -23.4% and Return on Assets is -9.4%, metrics that reveal the company is currently consuming capital to grow its business rather than generating returns on the invested equity or asset base.
Valuation Assessment
Valuation metrics present a complex picture for Tarsus Pharmaceuticals, with a trailing P/E ratio listed as N/A due to negative earnings, while the forward P/E is calculated at 23.16. The discrepancy between the non-existent trailing earnings and the specific forward P/E implies that the market is pricing the stock based on anticipated future profitability rather than historical performance. The price-to-book ratio stands at 8.27, indicating that the market values the company at more than eight times its book value, which suggests a significant premium placed on the company's intangible assets and intellectual property. Alternative valuation metrics include a price-to-sales ratio of 6.29 and an EV/EBITDA of -36.24, where the negative multiple reflects the current loss-making status but allows analysts to assess the company relative to its sales volume and enterprise value. The stock has traded between a 52-week low of $38.51 and a high of $85.25, placing the current valuation within a specific range relative to this historical volatility. With a beta of 0.60, the stock exhibits lower volatility than the broader market, suggesting that price movements are less sensitive to general market fluctuations compared to the average equity.
Growth & Income
Revenue growth for the trailing twelve months is reported at 128.4%, representing a more than doubling of annual sales, whereas earnings growth is listed as N/A due to the company's ongoing losses. The disparity between explosive revenue expansion and the absence of earnings growth implies that the company is prioritizing rapid market capture and pipeline advancement over immediate profitability. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders but instead reinvests all available capital and retained earnings into growth initiatives such as clinical trials and commercial expansion. This growth-focused profile is consistent with early-to-mid-stage biotechnology firms that must preserve cash reserves to achieve future monetization milestones. The overall profile combines aggressive revenue scaling with a disciplined reinvestment strategy, creating a high-risk, high-potential-reward dynamic typical of the sector where future commercial success is contingent on the successful development and approval of therapeutic candidates.